Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Brand Name Review By FDA: Predictability Returns To Process

Apr 18 2016

• By Kate Rawson

Related Content

The Name of the Game: Adjusting to a Tougher FDA Brand Name Review Process

Dec 01 2006

AstraZeneca's Vandetanib Approval Includes REMS With Distribution Restrictions

Apr 07 2011

What’s In A Name? Janssen’s Loss Of <em>Sovriad</em> Was Gilead’s Gain With <em>Sovaldi</em>

May 19 2014

FDA Rejecting Fewer Proprietary Names

Jan 02 2015

Related Companies

Johnson & Johnson

Gilead Sciences, Inc.

AstraZeneca PLC

Takeda Pharmaceutical Co. Ltd.

H. Lundbeck A/S

Additional Topics

United States Drug Approval Standards Advertising, Marketing & Sales Regulation Safety BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window